Research programme: macrocyclic peptide therapeutics - PeptiDream/Shionogi

Drug Profile

Research programme: macrocyclic peptide therapeutics - PeptiDream/Shionogi

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PeptiDream; Shionogi
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 12 Jun 2017 PeptiDream non-exclusively licenses its Peptide Discovery Platform System (PDPS) to Shionogi for use in development of macrocyclic peptides
  • 05 Feb 2016 Early research in Undefined indication in Japan (unspecified route)
  • 05 Feb 2016 Shionogi and PeptiDream agree to co-develop and co-promote macrocyclic/ constrained peptides in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top